OBX
NASDAQ HealthcareObsidian Therapeutics, Inc. - Common Stock
Biotechnology
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
๐ Market Data
| Price | $17.75 |
|---|---|
| Volume | 3,974,349 |
| Market Cap | 1.10B |
| Beta | 2.600 |
| RSI (14-Day) | 57.4 |
| 52-Week High | $49.97 |
| 52-Week Low | $14.57 |
| Forward P/E | -8.33 |
| Price / Book | -1.36 |
๐ฏ Investment Strategy Scores
OBX scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (94/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find OBX in your text
Paste any article, transcript, or post โ the tool will extract OBX and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.